TY - JOUR
T1 - Combination Intravesical Chemotherapy for Non–muscle-invasive Bladder Cancer
AU - Steinberg, Ryan L.
AU - Thomas, Lewis J.
AU - O'Donnell, Michael A.
N1 - Publisher Copyright:
© 2018 European Association of Urology
PY - 2018/7
Y1 - 2018/7
N2 - Bacillus Calmette-Guérin (BCG) replaced early intravesical chemotherapeutic agents as the standard of care for non–muscle-invasive bladder cancer (NMIBC) with its US Food and Drug Administration approval in 1990. Multiple studies have proven the superiority of BCG to surgery alone, and to older single-agent intravesical chemotherapy regimens. However, new multiagent intravesical chemotherapy regimens have been developed and tested in recent years. Such regimens offer the possibility of better efficacy and/or tolerability compared to BCG. However, high-quality data comparing such regimens to BCG remain scant. We briefly review the literature regarding combination intravesical chemotherapy for NMIBC. Combination intravesical chemotherapy is an understudied approach for non–muscle-invasive bladder cancer. Some treatment protocols have demonstrated promising results, but further follow-up and comparative analyses are needed.
AB - Bacillus Calmette-Guérin (BCG) replaced early intravesical chemotherapeutic agents as the standard of care for non–muscle-invasive bladder cancer (NMIBC) with its US Food and Drug Administration approval in 1990. Multiple studies have proven the superiority of BCG to surgery alone, and to older single-agent intravesical chemotherapy regimens. However, new multiagent intravesical chemotherapy regimens have been developed and tested in recent years. Such regimens offer the possibility of better efficacy and/or tolerability compared to BCG. However, high-quality data comparing such regimens to BCG remain scant. We briefly review the literature regarding combination intravesical chemotherapy for NMIBC. Combination intravesical chemotherapy is an understudied approach for non–muscle-invasive bladder cancer. Some treatment protocols have demonstrated promising results, but further follow-up and comparative analyses are needed.
KW - Chemotherapy
KW - Combination therapy
KW - Intravesical therapy
KW - Non–muscle-invasive bladder cancer
UR - http://www.scopus.com/inward/record.url?scp=85049851861&partnerID=8YFLogxK
U2 - 10.1016/j.euf.2018.07.005
DO - 10.1016/j.euf.2018.07.005
M3 - Review article
C2 - 30017900
AN - SCOPUS:85049851861
SN - 2405-4569
VL - 4
SP - 503
EP - 505
JO - European Urology Focus
JF - European Urology Focus
IS - 4
ER -